mik-beta-1

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namemik-beta-1
Drug Alias Nameanti-CD122 mAb (NCI)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionInterleukin-2 receptor beta chain modulators
TargetsInterleukin-2 receptor beta chain
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A